Диссертация (1139975), страница 17
Текст из файла (страница 17)
– 2009. - Vol. 373. – P. 309–317.64.Crawford DC, Akey DT, Nickerson DA. The patterns of natural variation inhuman genes // Annu Rev Genomics Hum Genet. – 2005. - Vol. 6. – P. 287-312.65.Cuisset T, Cayla G, Frere C, et al. Predictive value of post-treatment plateletreactivity for occurrence of post-discharge bleeding after non-ST elevation acutecoronary syndrome.
Shifting from antiplatelet resistance to bleeding riskassessment? // EuroIntervention. – 2009. - Vol. 5. – P. 325–329.66.Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole andpantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA(Proton Pump Inhibitors And Clopidogrel Association) prospective randomizedstudy // J Am Coll Cardiol. – 2009.
- Vol. 54. – P. 1149–1153.67.Cuisset T, Frere C, Quilici J, et al. Relationship between aspirin andclopidogrel responses in acute coronary syndrome and clinical predictors ofnonresponse // Thromb Res. – 2008. - Vol. 123. – P. - 597–603.68.valuesCuisset T, Frere C, Quilici J, Gaborit B, Castelli C, Poyet R, et al. Predictiveofpost-treatmentadenosinediphosphate-inducedaggregationandvasodilator-stimulated phosphoprotein index for stent thrombosis after acute116coronary syndrome in clopidogrel-treated patients // Am J Cardiol.
– 2009. - Vol.104. – P. 1078–1082.69.Cuisset T, Grosdidier C, Loundou AD, et al. Clinical implications of verylow on treatment platelet reactivity in patients treated with thienopyridine: thePOBA study (predictor of bleedings with antiplatelet drugs) // JACC CardiovascInterv. – 2013.
- Vol. 6. – P. 854–863.70.Dahl M-L. Cytochrome P450 phenotyping/genotyping in patients receivingantipsychotics: useful aid to prescribing? // Clin Pharmacokinet. – 2002. - Vol. 41.– P. 453–470.71.Dangas GD, Caixeta A, Mehran R, et al., Frequency and predictors of stentthrombosis after percutaneous coronary intervention in acute myocardial infarction// Circulation. – 2011. - Vol. 123. – P. 1745–1756.72.Davì G, Patrono C. Platelet activation and atherothrombosis // N Engl J Med/- 2007. - Vol.
357. – P. 2482–2494.73.De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a newgenetic defect responsible for the polymorphism of (S)-mephenytoin metabolism inJapanese // Mol Pharmacol. – 1994. - Vol. 46. – P. 594-598.74.De Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defectresponsible for the polymorphism of S-mephenytoin metabolism in humans // J BiolChem. – 1994.
- Vol. 269. – P. 15419-15422.75.Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochromeP450 2C19 genetic polymorphism // Clin Pharmacokinet. – 2002. - Vol. 41. –P.913-958.76.Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplateletdrugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American117college of chest physicians evidence-based clinical practice guidelines // Chest 2012. - Vol. -141(2 Suppl.). – P. e89S–e119S.77.El Desoky ES, Mohamed HO, Farghaly WM, et al.
Study of urinary 6 beta-hydroxycortisol/cortisol ratio in spot urine sample as a biomarker of 3A4 enzymeactivity in healthy and epileptic subjects of Egyptian population // Pharmacol Res. –2005. - Vol. 51. – P. 575-580.78.Elsenberg EH, van Werkum JW, van de Wal RM, et al.
The influence ofclinical characteristics, laboratory and inflammatory markers on ’high on-treatmentplatelet reactivity’ as measured with different platelet function tests // ThrombHaemost. – 2009. - Vol. 102. – P. 719–727.79.Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition byketoconazoleaffectsprasugrelandclopidogrelpharmacokineticsandpharmacodynamics differently // Clin Pharmacol Ther. – 2007.
- Vol. 81. – P. 735–741.80.Ferdinand KC. Cardiovascular Disease in Racial and Ethnic Minorities /Ferdinand KC, et al. – Springer, 2009. - 242 P.81.Frelinger AL, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics andpharmacodynamics vary widely despite exclusion or control of polymorphisms(CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications(including proton pump inhibitors), and pre-existent variability in platelet function// J Am Coll Cardiol.
– 2013. - Vol. 61. – P. 872-879.82.Fromm MF. The influence of MDR1 polymorphisms on P-glycoproteinexpression and function in humans //Adv Drug Deliv Rev. – 2002. - Vol. 54. – P.1295–1310.83.Gaikovitch EA, Cascorbi I, Mrozikiewicz PM et al.: Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-118glycoprotein in a Russian population // Eur J ClinPharmacol. – 2003. - Vol.
59. –P.303-312.84.Garabedian T, Alam S. High residual platelet reactivity on clopidogrel: itssignificance and therapeutic challenges overcoming clopidogrel resistance //Cardiovasc Diagn Ther. – 2013. - Vol. 3. – P. 23-37.85.Garfinkel D et al. Studies on pig liver microsomes. Enzymes and pigmentcomposition of different microsomal fractions // Arch Biochem Biophys. – 1958.Vol. 77. - P. 493-509.86.Ged C, Rouillon J, Pichard L et al. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction // BrJ Clin Pharmacol. – 1989.
- Vol. 28. – P. 373-387.87.Geisler T, Grass D, Bigalke B, et al. The residual platelet aggregation afterdeployment of intracoronary stent (PREDICT) score // J Thromb Haemost. – 2008.– Vol. 6. – P. 54-61.88.Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel isassociated with cardiovascular outcome after coronary stent implantation // EurHeart J. – 2006. - Vol. 27. – P. 2420–2425.89.Geisler T, Schaeffeler E, Dippon J, et al. CYP2C19 and nongenetic factors predictpoor responsiveness to clopidogrel loading dose after coronary stent implantation //Pharmacogenomics.
– 2008. – Vol. 9. – P. 1251–1259.90.Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplateletaction of clopidogrel associated with aspirin: the randomized, double-blind OCLA(Omeprazole CLopidogrel Aspirin) study // J Am Coll Cardiol. – 2008. – Vol. 51.– P.
256–260.11991.Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-offunction polymorphism to occurrence of drug-eluting coronary stent thrombosis //Am J Cardiol. – 2009. – Vol. 103. – P. 806–811.92.Goldstein J. A., de Morais S. M.
Biochemistry and molecular biology of the humanCYP2C subfamily // Pharmacogenetics. – 1994. – Vol. 4. – P. 285-299.93.Gurbel P, Erlinge D, Ohman E, et al. Platelet function during extended prasugreland clopidogrel therapy for patients with ACS treated without revascularization:the TRILOGY ACS platelet function substudy // JAMA. – 2012. – Vol. 308. – P.1785–1794.94.Gurbel PA, Antonino MJ, Bliden KP, et al. Platelet reactivity to adenosinediphosphate and long-term ischemic event occurrence following percutaneouscoronary intervention: a potential antiplatelet therapeutic target // Platelets. – 2008.– Vol. 19. – P.
595–604.95.Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects ofaspirin on platelet function: results from the Aspirin-Induced Platelet Effect(ASPECT) study // Circulation. – 2007. – Vol. 115. – P.3156–3164.96.Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: responsevariability, drug resistance, and the effect of pretreatment platelet reactivity //Circulation. – 2003.
– Vol. 107. – P. 2908–2913.97.Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management ofacute coronary syndromes in patients presenting without persistent ST-segmentelevation: the Task Force for the management of acute coronary syndromes (ACS)in patients presenting without persistent ST-segment elevation of the EuropeanSociety of Cardiology (ESC) // Eur Heart J.
– 2011. – Vol. 32. – P. 2999–3054.98.Hardwick JP. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acidmetabolism and metabolic diseases. Biochem Pharmacol. 2008;75(12):2263-75.12099.Harmsze AM, Robijns K, van Werkum JW, et al. The use of amlodipine, but not ofP-glycoprotein inhibiting calcium channel blockers is associated with clopidogrelpoor-response // Thromb Haemost. – 2010. – Vol. 103. – P. 920–925.100.Harmsze AM, van Werkum JW, Hackeng CM, et al. The influence ofCYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events inpatients undergoing elective coronary stenting // Pharmacogenet Genomics.
–2012. – Vol. 22. – P. 169-175.101.Harmsze AM, van Werkum JW, Ten Berg JM, et al. CYP2C19*2 andCYP2C9*3 alleles are associated with stent thrombosis: a case-control study // EurHeart J. – 2010. – Vol.31. – P. 3046–3053.102.Hazarbasanov D, Velchev V, Finkov B, et al. Tailoring clopidogrel doseaccording to multiple electrode aggregometry decreases the rate of ischemiccomplications after percutaneous coronary intervention // J Thromb Thrombolysis.– 2012. – Vol.34.
– P. 85-90.103.Hobl EL, Stimpfl T, Ebner J, et al. Morphine decreases clopidogrelconcentrations and effects: a randomized, double-blind, placebo-controlled trial // JAm Coll Cardiol. – 2014. – Vol. 63. – P. 630-635.104.Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-functionpolymorphism is a major determinant of clopidogrel responsiveness in healthysubjects // Blood. – 2006. – Vol. 108. – P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
